Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of 2-Fluorofucose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Fluorofucose SCHEMBL31427535 | 1.00 | TP53 (0.32) | TP53FFAR3LCKFYN | |
| 2-Fluorofucose SCHEMBL29709536 | 0.93 | — | — | |
| 2-Fluorofucose SCHEMBL20560114 | 0.93 | — | — | |
| 2-Fluorofucose SCHEMBL8578272 | 0.93 | — | — | |
| 2-Fluorofucose SCHEMBL570873 | 0.93 | — | — | |
| Acetic Acid SCHEMBL570874 | 0.73 | TP53 (0.32) | TP53FFAR3LCKFYN | |
| L-Fucose SCHEMBL11415694 | 0.71 | LMNA (0.30) | — | |
| SCHEMBL18255996 | 0.71 | — | — | |
| SCHEMBL10527951 | 0.70 | — | — | |
| SCHEMBL10703663 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11033561-B2 | Methods of inhibition of protein fucosylation in vivo using fucose analogs | SEAGEN INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200061091-A1 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | SEATTLE GENETICS, INC. (US) | 2020-02-27 | — | — | US | disclosed |
| EP-3513794-A2 | FUCOSE ANALOGS FOR INHIBITION OF PROTEIN FUCOSYLATION IN VIVO | Seattle Genetics, Inc. (US) | 2019-07-24 | — | — | EP | disclosed |
| US-10342811-B2 | Methods of inhibition of protein fucosylation in vivo using fucose analogs | SEATTLE GENETICS, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| EP-2608796-B1 | INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | SEATTLE GENETICS INC (US) | 2018-11-21 | — | — | EP | disclosed |
| US-20170035790-A1 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | SEATTLE GENETICS, INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9504702-B2 | Methods of inhibition of protein fucosylation in vivo using fucose analogs | SEATTLE GENETICS, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| EP-2608796-A2 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | Seattle Genetics, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20130129784-A1 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | SEATTLE GENETICS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2012019165-A2 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | SEATTLE GENETICS, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035790-A1 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | FUCA1, FUCA2, FUT4 | TP53 3911/4885FFAR3 3193/4885LCK 1562/4885 |
| US-10342811-B2 | Methods of inhibition of protein fucosylation in vivo using fucose analogs | FUCA1, FUCA2, FUT4 | TP53 3911/4885FFAR3 3193/4885LCK 1562/4885 |
| US-20200061091-A1 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | FUCA1, FUCA2, FUT4 | TP53 3911/4885FFAR3 3193/4885LCK 1562/4885 |
| US-11033561-B2 | Methods of inhibition of protein fucosylation in vivo using fucose analogs | FUCA1, FUCA2, FUT4 | TP53 3911/4885FFAR3 3193/4885LCK 1562/4885 |
| US-20130129784-A1 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | FUCA1, FUCA2, FUT4 | TP53 3911/4885FFAR3 3193/4885LCK 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.